Navigation Links
QRxPharma Granted Additional US Patent on MoxDuo®
Date:5/23/2012

SYDNEY and BEDMINSTER, N.J., May 23, 2012 /PRNewswire/ -- QRxPharma Limited (ASX: QRX and OTCQX: QRXPY) announced today that the United States Patent and Trademark Office (USPTO) issued the Company U.S. Patent No. 8,182,837, which does not expire until 2023.  This patent covers a method of treatment of pain comprising the administration of the oral Dual Opioid® compositions of MoxDuo IR (Immediate Release) for the treatment of acute pain as well as MoxDuo CR (Controlled Release) for the treatment of chronic pain.

"This patent is a key component of our intellectual property (IP) portfolio that provides long term market exclusivity for QRxPharma's MoxDuo opioid products for the treatment of acute and chronic pain," said Dr. John Holaday, Managing Director and Chief Executive Officer.  "This issued patent expands our global IP protection as we look to the commercialisation of our first product, MoxDuo IR, in the third quarter of this year."

The original composition of matter patent granted by the USPTO (U.S. Patent No. 6,310,072) covers the combination of morphine and oxycodone and provides coverage until 2016.  The newly issued patent is directed to a method of treatment of pain using MoxDuo's composition as defined ratio of morphine/oxycodone (3/2), and will not expire until 2023.  Further patents granted in 2011 (U.S. Patents Nos. 7,923,453 and 8,012,990) extend MoxDuo IR IP protection to 2029 and cover a proprietary dosing algorithm for converting patients from intravenous opioid administration to MoxDuo IR, thereby more effectively and safely managing acute pain following surgery.

In April, QRxPharma announced the successful completion of two Phase 1 studies in healthy volunteers for MoxDuo CR, a controlled-release Dual-Opioid utilising a 3:2 ratio of morphine and oxycodone.  The proprietary MoxDuo CR formulation, encompassing both sustained delivery technology as well as abuse deterrent and tamper resistant features, is the subject of additional pending global patent applications.

About QRxPharma
QRxPharma Limited (ASX: QRX and OTCQX: QRXPY) is a commercial-stage specialty pharmaceutical company focused on the development and commercialisation of new treatments for pain management. Based on a development strategy that focuses on enhancing and expanding the clinical utility of currently marketed compounds, the Company's product portfolio includes both late and early stage clinical drug candidates with the potential for reduced risk, abbreviated development paths, and improved patient outcomes.  QRxPharma's lead product candidate, immediate release MoxDuo, has a Prescription Drug User Fee Act (PDUFA) date of 25 June 2012 when the New Drug Application review by the US Food and Drug Administration (FDA) will be completed. The Company is partnered with Actavis, Inc. to commercialise MoxDuo IR in the US acute pain market, with product launch anticipated in 3Q, CY2012. QRxPharma may co-promote its products in the US and plans to seek strategic partnerships for worldwide markets. Additionally, the Company's clinical pipeline includes an intravenous (IV) and continuous release (CR) formulation of MoxDuo. For more information, visit www.qrxpharma.com.

Forward Looking Statements
This release contains forward-looking statements. Forward-looking statements are statements that are not historical facts; they include statements about our beliefs and expectations. Any statement in this release that states our intentions, beliefs, expectations or predictions (and the assumptions underlying them) is a forward-looking statement. These statements are based on plans, estimates and projections as they are currently available to the management of QRxPharma. Forward-looking statements therefore speak only as of the date they are made, and we undertake no obligation to update publicly any of them in light of new information or future events. By their very nature, forward-looking statements involve risks and uncertainties. A number of important factors could therefore cause actual results to differ materially from those contained in any forward-looking statement. Such factors include risks relating to the stage of products under development; uncertainties relating to clinical trials; dependence on third parties; future capital needs; and risks relating to the commercialisation of the Company's proposed products.


'/>"/>
SOURCE QRxPharma Limited
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. QRxPharma Doses First Patients in Phase III Clinical Trial Program for its Dual Opioid Pain Therapy
2. QRxPharma Releases Successful Phase 3 Study Results for Dual Opioid Pain Therapy
3. QRxPharma Releases Additional Phase 3 Data for Q8003IR Dual Opioid Pain Therapy
4. QRxPharma Successfully Completes Comparative Study for Dual-Opioid(TM) Pain Therapy
5. QRxPharma Inks Deal with Patheon for the Manufacture of MoxDuo(TM)CR
6. QRxPharma Limited Announces A$21.6 Million Fully Underwritten Capital Raising
7. QRxPharma Initiates Second Pivotal Phase 3 Study of MoxDuo(TM)IR Dual-Opioid(TM) for NDA Submission
8. QRxPharma Limited and China Aoxing Pharmaceutical Company Announce Strategic Alliance for Development of MoxDuo(R)IV
9. QRxPharma Releases Additional Pivotal Phase 3 Combination Rule Study Data for MoxDuo(R)IR in Patients with Post-Surgical Pain
10. QRxPharma Successfully Completes Comparative Phase 1 Proof-of-Concept Study for MoxDuo(R) CR Tablet Formulation
11. QRxPharma Receives Positive Feedback from Scientific Advice Meetings in Europe on MoxDuo®IR Development and Registration
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/18/2017)... , January 18, 2017 The report " Automated Breast ... Breast Volume Scanner), By End User (Hospitals, Diagnostic Imaging Centers), Industry Analysis Report, ... Argentina , Germany , UK, ... Russia , China , Japan ... Thailand , Saudi Arabia , UAE, ...
(Date:1/18/2017)... Jan. 18, 2017  Eisai Inc., the U.S. ... that it is participating in Access Accelerated, a ... (NCDs) prevention, treatment and care in low and ... the first multi-stakeholder, international initiative in the field ... including Eisai, in collaboration with the World Bank ...
(Date:1/18/2017)... After the recent election cycle, it ... cannabis both for medical and recreational purposes are shifting. The ... the use of cannabis, but the focus is coming from ... Research, the North American legal cannabis market posted $6.7 billion ... The research projects sales will grow at a compound annual ...
Breaking Medicine Technology:
(Date:1/17/2017)... , ... January 17, 2017 , ... Gym Source, America’s ... a new showroom at South Dixie Hwy in Miami, FL. , “We are elated ... Source. “The new innovative in-store concept is designed to give clients a seamless and ...
(Date:1/17/2017)... Los Angeles, CA (PRWEB) , ... January 17, ... ... conflicted and concerned by the political/social/economic events, Dr. Carol Francis re-releases powerfully uplifting ... tragedies and magical moments that help everyone endure and pass through tough times, ...
(Date:1/17/2017)... Florida (PRWEB) , ... January 17, 2017 , ... Kevin ... Producers of AsSeenOnTV.pro will be featuring DRTV campaigns regarding the topic of Beauty and ... become a better version of themselves. What better way to commit to these changes ...
(Date:1/17/2017)... ... January 17, 2017 , ... ... as Palm Desert, is opening a new office in San Clemente, California this ... stimulation (dTMS) in Southern California, successfully treating individuals struggling with major depression. Depression ...
(Date:1/17/2017)... ... January 17, 2017 , ... Peoples Health is pleased to ... on Dec. 1, 2016. Peoples Health, a Metairie-based Medicare Advantage company, serves more ... addition to our provider network, and the addition will benefit our members in ...
Breaking Medicine News(10 mins):